| Filed On | Filing |
|---|---|
| 29 Oct 2026 |
8-K: Other Events
Virtual Investor Day October 29, 2026 Nasdaq: XFOR Exhibit 99.1 |
| 08 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +3 more
- Strengthens Financial Flexibility with Access to Funding for Corporate and Commercial Activities - |
| 09 Sep 2026 |
8-K: Other Events
Corporate Presentation September 2026 Nasdaq: XFOR EXHIBIT 99.1 |
| 08 Sep 2026 |
8-K: Other Events
- FDA Agrees to Reduced Sample Size for the Global 4WARD Phase 3 Chronic Neutropenia Trial - |
| 01 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
BOSTON, July 1, 2026 – X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the appointment of Kelly Gold to the Company’s Board of Directors effective July ... |
| 12 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
The purpose of this Second Amended and Restated 2017 Equity Incentive Plan (the “Plan”) of X4 Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Compa... |
| 05 Nov 2025 |
8-K: Results of Operations and Financial Condition
Company’s strategic focus and highest priority is now the advancement of the 4WARD Phase 3 chronic neutropenia trial |
| 27 Oct 2025 |
8-K: Entry into a Material Definitive Agreement
Pre-Funded Warrants to Purchase 700,000 Shares of Common Stock |
| 17 Sep 2025 |
8-K: Costs Associated with Exit or Disposal Activities; Departure/Election of Directors or Officers; Compensation +1 more
Organizational restructuring including a 50% reduction in workforce that is anticipated to result in annualized cost savings of approximately $13M |
| 25 Aug 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 13 Aug 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of August 12, 2025 by and among X4 Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (... |
| 12 Aug 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of August 11, 2025 by and among X4 Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (... |
| 23 Jun 2025 |
8-K: Entry into a Material Definitive Agreement
THIS PURCHASE AGREEMENT (the "Agreement"), dated as of June 23, 2025, is made by and between X4 PHARMACEUTICALS, INC., a Delaware corporation (the "Company"), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the... |
| 11 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 9, 2025, X4 Pharmaceuticals Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”), at which a quorum was present. The final results for each of the proposals submitted to a vote of the Company’s stoc... |
| 01 May 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
4WARD Phase 3 chronic neutropenia trial in full swing; full enrollment on track for 3Q or 4Q 2025 and top-line data in 2H 2026 |
| 24 Apr 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Other Events
CERTIFICATE OF AMENDMENTTORESTATED CERTIFICATE OF INCORPORATIONOFX4 PHARMACEUTICALS, INC. |
| 18 Apr 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On April 17, 2025, X4 Pharmaceuticals, Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”) at 8:00 a.m. Eastern Time for the purposes of considering and voting upon the proposals below. As of the record da... |
| 25 Mar 2025 |
8-K: Results of Operations and Financial Condition
Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; |
| 03 Mar 2025 |
8-K: Other Events
As previously disclosed on a Current Report on Form 8-K filed by X4 Pharmaceuticals, Inc. (the “Company”), on August 13, 2024, the Company received a deficiency letter (the “Nasdaq Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) not... |
| 06 Feb 2025 |
8-K: Costs Associated with Exit or Disposal Activities; Regulation FD Disclosure
X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia |
Loading...